Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(118 products)
- EGFR(582 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2382 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/VEGFR2-IN-1
EGFR/VEGFR2-IN-1 (Compound 10e) serves as an inhibitor for VEGFR-2 and EGFR, with respective IC50 values of 0.26 and 0.14 μM. It inhibits microtubule protein polymerization with an IC50 of 40.9 μM and induces cell apoptosis (Apoptosis). EGFR/VEGFR2-IN-1 is applicable in research related to anti-leukemia and anti-lymphoma treatments.Color and Shape:Odour SolidErlotinib-13C6
CAS:Erlotinib-13C6 (CP-358774-13C6), a 13C-labeled direct EGFR inhibitor, IC50: 2 nM.Formula:C22H23N3O4Color and Shape:SolidMolecular weight:399.397BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93EGFR-IN-116
EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.Formula:C26H22N6O2SMolecular weight:482.1525MR44397
MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54FAK-IN-9
CAS:FAK-IN-9 (8f) is a potent oral FAK inhibitor, IC50 of 27.44 nM; induces TNBC cell apoptosis.Formula:C36H38ClN7O8SColor and Shape:SolidMolecular weight:764.25PROTAC BTK Degrader-6
CAS:PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFormula:C45H47N11O6Purity:98%Color and Shape:SolidMolecular weight:837.92Lyn peptide inhibitor
CAS:Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.Formula:C115H184N30O24Purity:98%Color and Shape:SolidMolecular weight:2370.91SNIPER(ABL)-033
CAS:SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL proteinFormula:C61H73F3N10O9S2Purity:98%Color and Shape:SolidMolecular weight:1211.42SNIPER(ABL)-013
SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 ofFormula:C42H52F3N7O8Purity:98%Color and Shape:SolidMolecular weight:839.9VnP-16
VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activatesFormula:C82H112N20O17Purity:98%Color and Shape:SolidMolecular weight:1649.89PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formula:C46H50F3N13O8Purity:98%Color and Shape:SolidMolecular weight:969.97EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formula:C50H55ClFN5O5Color and Shape:SolidMolecular weight:860.45LC-SF-14
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.Formula:C44H50Cl3N13O5SColor and Shape:SolidMolecular weight:977.28442FLT3-IN-22
FLT3-IN-22 (compound 22f) is a potent inhibitor of FLT3, demonstrating IC50 values of 0.941 nM for FLT3 and 0.199 nM for the FLT3/D835Y mutant.Formula:C24H22N6O2Color and Shape:SolidMolecular weight:426.47MS9427 TFA
MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.Formula:C50H59ClF4N8O14Color and Shape:SolidMolecular weight:1107.5VEGFR-2-IN-64
VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.Formula:C72H123N9O6Color and Shape:SolidMolecular weight:1210.83-Methylthienyl-carbonyl-JNJ-7706621
CAS:Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Formula:C14H14N6O3S2Color and Shape:SolidMolecular weight:378.43PROTAC FAK degrader 1
CAS:PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).Formula:C47H56F3N9O8S2Purity:98%Color and Shape:SolidMolecular weight:996.13PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formula:C22H22FN5O2Color and Shape:SolidMolecular weight:407.44AXL/Angiokinase-IN-1
AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.Formula:C31H34ClN5O2Color and Shape:SolidMolecular weight:544.09VEGFR-2-IN-56
VEGFR-2-IN-56 (compound 12e) exhibits the strongest inhibition activity against VEGFR-2, with an IC50 value of 45.9 nM.Color and Shape:Odour SolidhCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Formula:C21H17FN6O3SPurity:98%Color and Shape:SolidMolecular weight:452.46ZSH-2117
ZSH-2117 is a covalent and selective EGFR PROTAC degrader, with a DC50 of 45 nM in Ba/F3-EGFR[L858R/T790M/C797S] cells. It significantly inhibits cell proliferation and reduces AKT and ERK protein levels in downstream EGFR signaling pathways. ZSH-2117 effectively suppresses tumor growth in Ba/F3-EGFR[L858R/T790M/C797S] xenograft mouse models.Color and Shape:Odour SolidCPD-1224
CAS:CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.Formula:C43H47ClN8O7SColor and Shape:SolidMolecular weight:855.4FLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsColor and Shape:Odour SolidTYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485WDR5 ligand 2
CAS:WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.Formula:C29H31F3N4O4Color and Shape:SolidMolecular weight:556.576EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55Caffeic acid-pYEEIE
CAS:Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).
Formula:C39H50N5O19PPurity:98%Color and Shape:SolidMolecular weight:923.82SI-2
CAS:SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.Formula:C15H15N5Purity:98.4%Color and Shape:SolidMolecular weight:265.31Ref: TM-T28773
1mg358.00€5mg873.00€10mg1,161.00€25mg1,755.00€50mg2,358.00€100mg3,177.00€1mL*10mM (DMSO)800.00€GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9PROTAC EGFR degrader 10
CAS:PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.Formula:C49H65ClN10O7SColor and Shape:SolidMolecular weight:973.62DSPE-PEG1000-GE11
DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.Color and Shape:Odour Solid7-Hydroxyneolamellarin A
CAS:7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Formula:C24H19NO5Color and Shape:SolidMolecular weight:401.41Candidalysin
CAS:Candidalysin is a cytolytic peptide toxin initially isolated from *Candida albicans*, exhibiting both toxic and non-toxic properties. It activates epithelial cell signaling pathways by interacting with the epithelial growth factor receptor (EGFR) on host cells, leading to the activation of matrix metalloproteinases (MMP) and calcium ion influx, which results in inflammatory responses and immune cell recruitment. Additionally, Candidalysin exhibits cytotoxicity by causing membrane damage to host cells.Formula:C153H266N38O38S2Color and Shape:SolidMolecular weight:3310.11ALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Formula:C24H30ClN6O2PColor and Shape:SolidMolecular weight:500.97Anti-FLT3 Antibody (AGS62P)
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3 for research in acute myeloid leukemia.Color and Shape:Odour LiquidHER2/neu (654-662) GP2
CAS:Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.Formula:C42H77N9O11Purity:98%Color and Shape:SolidMolecular weight:884.11EGFR T790M/L858R-IN-6
CAS:EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].Formula:C27H27N7O2Color and Shape:SolidMolecular weight:481.55VEGFR-2/InhA-IN-1
VEGFR-2/InhA-IN-1, a dual inhibitor based on pyrazole, targets InhA and VEGFR, exhibiting both anti-tuberculosis and anti-angiogenic properties. It demonstrates effective antibacterial activity against the Mycobacterium tuberculosis H37Rv strain (MIC = 6.25 μg/mL) and significantly suppresses VEGFR-2 activity (IC 50 = 15.27 nM).Formula:C22H16ClFN4OColor and Shape:SolidMolecular weight:406.84EGFR-IN-120
EGFR-IN-120 (Compound 11eg) is an orally effective EGFR inhibitor. It exhibits potency against the EGFR L858R/T790M/C797S mutant with an IC50 of 0.053 μM, and displays weaker activity against EGFRWT, with an IC50 of 1.05 μM. EGFR-IN-120 inhibits the phosphorylation of EGFR as well as key downstream effectors including STAT3, AKT, and Erk. This compound induces cell cycle arrest and apoptosis in cells harboring the EGFR mutation. Additionally, EGFR-IN-120 inhibits the proliferation of NSCLC cells containing the EGFR L858R/T790M/C797S mutation, with an IC50 value of 0.052 μM.Color and Shape:Odour SolidDC-Srci-6649
CAS:DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.Formula:C20H22Cl2N2O2SColor and Shape:SolidMolecular weight:425.37JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7TX2-120-1
CAS:TX2-120-1 possesses the ability to bind with Her3, exhibiting an IC50 of 56 nM for Her3. It can be utilized in the synthesis of TX2-121-1.Formula:C26H27N7O2Color and Shape:SolidMolecular weight:469.54AST5902
CAS:AST5902 is the active metabolite of Alflutinib.Formula:C27H29F3N8O2Purity:98%Color and Shape:SolidMolecular weight:554.57EGFR-IN-153
EGFR-IN-153 (Compound 5l) is an EGFR inhibitor that suppresses the proliferation of MDA-MB-231 cells with an IC50 of 0.73 μM and induces apoptosis. It is applicable for research in breast cancer.Color and Shape:Odour SolidPROTAC BCR-ABL1 ligand 1
CAS:GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.Formula:C17H12F3N3O2Color and Shape:SoildMolecular weight:347.29FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formula:C29H35N7O5Color and Shape:SolidMolecular weight:561.63FAK-IN-24
CAS:FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.Formula:C39H45Cl2F3N8O3Color and Shape:SolidMolecular weight:801.728
